NCT05075070

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With Human Immunodeficiency Virus Infected

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: China National Biotec Group Company Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of immunogenicity and safety of the subjects infected with HIV to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days .

Detailed description

The subjects infected with HIV were recruited to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days . Blood samples will be collected 2 times: before the 1st dose of vaccinatioin and 28 days after the 2nd dose of vaccination. Any local or systemic adverse events that occurred within 21 days after vaccination will be recorded.

Conditions

• COVID-19
• HIV Infections

Interventions

Type	Name	Description
BIOLOGICAL	Inactivated COVID-19 vaccine	two doses inactivated COVID-19 vaccine

Timeline

• Start date: 2021-10-08
• Primary completion: 2022-06-30
• Completion: 2022-06-30
• First posted: 2021-10-12
• Last updated: 2021-10-22

Locations

1 site across 1 country: China